VEGF
42 programs · 40 companies
Programs
42
Companies
40
Active Trials
30
Targeting VEGF
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | OCDT2D | |
| TAK-8730 | Takeda | Phase 2 | Breast CaCholangiocarcinoma | |
| GIL-2011 | Gilead Sciences | Preclinical | Heart Failure | |
| Bemazumab | Regeneron | Phase 1 | HCCEoE | |
| Pemicapivasertib | Legend Biotech | Phase 3 | HNSCC | |
| Sematapinarof | Legend Biotech | NDA/BLA | MDDSCD | |
| LEG-6533 | Legend Biotech | NDA/BLA | MigraineGA | |
| ASN-7038 | Ascendis Pharma | Phase 3 | CSUBladder Ca | |
| Pemisertib | Zymeworks | NDA/BLA | MigrainePTSD | |
| Tezetapinarof | CG Oncology | Phase 3 | FTD | |
| 450-7253 | Shionogi | Approved | PNH | |
| SEO-IIT-400 | Seoul Natl Univ Hosp | NDA/BLA | SCLC | |
| Rimatinib | Boundless Bio | NDA/BLA | ADHDSCLC | |
| Tixasotorasib | Vesalius Ther | Approved | Wet AMD | |
| Pemiderotide | Adagene | Phase 2/3 | CKD | |
| Mavuinavolisib | TransCode Therapeutics | Preclinical | CSUGBM | |
| APT-1263 | Aptinyx | Phase 1 | LN | |
| Mavucagene | Athenex | Phase 1/2 | RettRB | |
| Capilemzoparlimab | Cirius Therapeutics | Phase 2 | PBCBladder Ca | |
| Tezecilimab | Volato Group | Approved | NB | |
| Olpalemzoparlimab | Compugen | Approved | SLE | |
| SIE-9908 | Sierra Oncology (GSK) | Phase 3 | Ovarian Ca | |
| 208-7575 | PharmAbcine | Phase 2/3 | GISTADHD | |
| Ivocilimab | Generate Bio | NDA/BLA | AsthmaObesity | |
| 128-2997 | Hanmi Pharma | Phase 1/2 | CFHS | |
| IPH-2316 | Innate Pharma | Preclinical | Alzheimer'sMS | |
| Fixalucimab | Almirall | Phase 2 | Cervical Ca | |
| Capitenlimab | Starpharma | Phase 1 | ALS | |
| Capirapivir | Molecular Partners | Approved | ALSCervical Ca | |
| TES-1600 | Tessa Therapeutics | Phase 1/2 | CKD | |
| ZYD-7355 | Zydus Lifesciences | Phase 1 | Melanoma | |
| BIO-IIT-157 | Bio-Manguinhos | Phase 1 | NB | |
| JAM-4301 | Jamjoom Pharma | Phase 1/2 | Narcolepsy | |
| ABD-3507 | Abdi Ibrahim | Preclinical | DravetMigraine | |
| INS-IIT-597 | Institut Curie | Phase 2/3 | LGS | |
| FUD-IIT-133 | Fudan Cancer Hosp | Phase 1/2 | Hemophilia A | |
| WES-IIT-873 | West China Hosp | Phase 2/3 | MCL | |
| SQU-6405 | Square Pharma | Phase 2/3 | PBCMG | |
| Lisozasiran | Gedeon Richter | NDA/BLA | GISTSCD | |
| Kematenlimab | LEO Pharma | Phase 2/3 | SchizophreniaWet AMD | |
| THE-3484 | Theramex | Phase 1 | Crohn's | |
| DEC-4099 | Dechra Pharma (EQT) | Phase 3 | RSVCervical Ca |